Monitor upcoming 10-Q for updates on cash position and R&D progress. The Interim CEO’s purchase may signal confidence, but given recent dilution and leadership turnover, treat this as a cautious positive rather than a strong catalyst. Compare future Form 4 filings to see if buying continues.
Price Chart
Executive Summary
Two corporate insiders at Hepion Pharmaceuticals, including the Interim CEO, purchased $100,000 worth of shares in open-market transactions on April 21, 2026, at $0.04 per share. This buying activity follows a recent CEO departure, a dilutive $700,000 private placement, and a separation agreement with the former CEO, suggesting leadership may be signaling confidence amid financial and governance challenges.
Key Financial Metrics
Key Facts
- Interim CEO Gary Stetz and Director Sireesh Appajosyula each purchased 1.25 million shares at $0.04, totaling $50,000 per transaction.
- Total insider buying cluster value: $100,000 over a 7-day window.
- Transactions occurred just days after a dilutive private placement and the formal separation from former CEO Dr. Kaouthar Lbiati.
- All purchases were open-market buys, indicating use of personal capital to acquire stock.
Financial Impact
$100,000 in open-market purchases, representing 0.014% of the company's ~$714M market cap (based on $0.04 share price and 17.85B shares outstanding).
Risk Factors
- Recent $700,000 private placement at the same $0.04 price implies ongoing capital needs and potential further dilution.
- Departure of the CEO and reliance on interim leadership raises governance concerns.
- Low trading volume and OTC listing increase execution and liquidity risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-HEPA-1777285513384 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | $0.1310 | awaiting T+20 | — | $0.1310 (−0.00%) |
Oct 21, 2026 5d ago | SC 13G/A | $0.1350 | awaiting T+20 | — | $0.1310 (−2.96%) |
Oct 9, 2026 17d ago | 8-K | $0.1240 | awaiting T+20 | — | $0.1310 (+5.65%) |
Sep 28, 2026 29d ago | 8-K | $0.0800 $0.1281 | ▼ −60.13% | ▼ −60.16% | $0.1310 (−63.75%) |
Aug 12, 2026 10w ago | Insider Cluster | $0.0700 $0.0550 | ▼ −21.43% | ▼ −19.68% | $0.1310 (+87.14%) |
Apr 21, 2026 27w ago | Insider Cluster | $0.0700 $0.0750 | ▲ +7.14% | ▲ +1.67% | $0.1310 (+87.14%) |
Apr 21, 2026 27w ago | Insider Cluster | $0.0620 $0.0750 | ▲ +20.97% | ▲ +16.01% | $0.1310 (+111.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers